- New strategic collaboration to develop and commercialize bispecific immuno-oncology antibodies, including LAG-3/PD-L1 asset FS118
- Potential for Merck KGaA, Darmstadt, Germany to rapidly expand its immuno-oncology portfolio, supporting the goal to be a leader in this area of research
Darmstadt, Germany, June 4, 2017 – Merck KGaA, Darmstadt, Germany, a leading science and technology company which operates its biopharmaceutical business as EMD Serono in the U.S. and Canada, today announced a new strategic collaboration with biopharmaceutical company F-star, Cambridge, UK, for the development and commercialization of five bispecific immuno-oncology antibodies. Beyond these five bispecific antibodies, Merck KGaA, Darmstadt, Germany will have further rights to replace, as well as to add to these antibodies using F-star’s bispecific antibody platform. This collaboration will further strengthen Merck KGaA, Darmstadt, Germany’s immuno-oncology pipeline and underscores the commitment to discovering and developing breakthrough cancer therapies that make a meaningful difference to patients’ lives.
“Our collaboration with F-star will help us to rapidly enhance our pipeline and grow our portfolio of bispecific immunotherapies,” said Luciano Rossetti, Executive Vice President, Global Head of Research & Development at the biopharma business of Merck KGaA, Darmstadt, Germany. “This deal complements our internal capabilities?in immuno-oncology and positions us as a potential leader in this important area of research.”
Under these agreements and upon delivery of pre-defined data packages, Merck KGaA, Darmstadt, Germany has the option to acquire five of F-star’s bispecific programs. This option includes exclusive development and commercialization rights to F-star’s preclinical lead asset FS118, which is designed to block LAG-3 (Lymphocyte-Activation Gene 3) and PD-L1 (Programmed Death-Ligand 1), two pathways commonly used by cancer cells to evade the immune system. In addition, F-star will grant Merck KGaA, Darmstadt, Germany exclusive development and commercial rights to four novel bispecific antibodies of Merck KGaA, Darmstadt, Germany’s choosing from F-star’s bispecific antibody platform. These bispecific antibodies target specific pathways to augment the anti-tumor immune response. In return, Merck KGaA, Darmstadt, Germany will pay up to €115 million in upfront, R&D funding and milestone payments in the first 2 years, and may make further payments upon exercising its option and based on milestones.
Merck KGaA Darmstadt, Germany already has a bifunctional antibody in its pipeline, M7824. Currently in Phase I, M7824 is believed to combine two mechanisms in one molecule to fight cancer. The addition of assets from F-star’s bispecific antibody platform enrich and complement Merck KGaA Darmstadt, Germany’s existing inhouse technologies investigating molecules that offer the potential advantage of taking a dual approach to tackling cancer. Discovered in-house, M7824 is an investigational immunotherapy designed to simultaneously block two immunoinhibitory pathways (PD-L1 and TGF-β) that are commonly used by cancer cells to evade the immune system.
“This immuno-oncology collaboration expands our strong relationship with Merck KGaA, Darmstadt, Germany and is a further validation of the potential of F-star’s bispecific antibody platform,” said John Haurum, CEO of F-star. “Our vision is to transform the treatment of cancer. This is the objective of partnering our lead asset FS118 and other next-generation immuno-oncology compounds with Merck KGaA, Darmstadt, Germany.”
Merck KGaA, Darmstadt, Germany is committed to exploring an array of targets, and taking creative scientific approaches to developing novel therapies for hard-totreat cancers. With the belief that rational combination is the key to the future of new and more efficacious treatment options, Merck KGaA, Darmstadt, Germany has a particular focus on combination therapies, whether it be with chemotherapy/radiotherapy, other targeted therapies and/or immunotherapies from its own or external portfolios. The strength of Merck KGaA, Darmstadt, Germany’s promising oncology development program and growing presence in the field of immuno-oncology demonstrates how the company is re-imagining the way cancer care is delivered.
For further information and press materials on Merck KGaA, Darmstadt, Germany activities in oncology, please visit